Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

Completed

Looking for future studies?

Key information

Conditions

Asthma, Bronchial Asthma Bronchial Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Aspiration Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Pleven, Bulgaria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of asthma
Patients treated with inhaled corticosteroid
FEV1 (forced expiratory volume in 1 second)>60% to 80%

Exclusion criteria

Respiratory infection within 2 weeks
Asthma exacerbation within 90 days

Treatment and study plan

Tacrolimus

Drug

Sponsors and collaborators

Lead sponsor

Astellas Pharma Inc

Industry

Collaborators

Astellas Pharma Europe B.V.

Registry information

Important dates

Primary completion: 2005
Study completion: 2005
First posted: Sep 19, 2005
Registry last updated: Apr 17, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed